involves numerous collaborations with agencies such as MOHs, WHO, UNICEF, and the World Bank. Domestically, as the largest supplier of blood in the U.S., ARC is uniquely positioned to collaborate with Federal agencies and AIDS control program officials in blood safety.

6. ARC has access to a wealth of HIV/AIDS resources that may be adapted, both from its domestic programs and its international initiatives, such as the ARCHI tool kits and the Federation’s Action with Youth, HIV/AIDS STDs: A Training Manual for Young People. Additionally, ARC and the Federation have expertise in establishing regional networking mechanisms for dissemination of information and lessons learned. For example, the “Caribbean Youth HIV/AIDS Network” (CARAN) and the “Asian Red Cross/Red Crescent Task Force on HIV/AIDS” (ART) are models that are being replicated in West Africa.

7. ARC has already developed a range of technical services domestically, including instructor training courses, communication and cooperation in sharing Red Cross HIV/AIDS information and resources on a statewide basis in the U.S., support of home care for people living with HIV/AIDS, and prevention among youth through peer-to-peer education programs. Through the Federation, ARC is uniquely positioned to disseminate this information to national AIDS control program officials in LIFE countries.

Note: Public Law 104–65 states that an organization described in section 501(c)(4) of the Internal Revenue Code of 1986 that engages in lobbying activities is not eligible to receive Federal funds constituting an award, grant, cooperative agreement, contract, loan or any other form.

C. Availability of Funds

Approximately $3 million is available in FY 2000 to support this award. It is expected that the award will begin on or about September 1, 2000, and will be made for a 12-month budget period within a project period of up to 3 years. Funding estimates may change. Continuation awards within an approved project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

Use of Funds

Funds received from this announcement will not be used for the purchase of antiretroviral drugs for treatment of established HIV infection, occupational exposures, and non-occupational exposures and will not be used for the purchase of machines and reagents to conduct the necessary laboratory monitoring for patient care.

Applicants may contract with other organizations under these cooperative agreements, however, applicants must perform a substantial portion of the activities (including program management and operations and delivery of prevention services for which funds are requested).

D. Where To Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address—http://www.cdc.gov. Scroll down the page, then click on “Funding” then “Grants and Cooperative Agreements.”

To receive additional written information and to request an application kit, call 1–888–GRANTS4 (1–888–472–6874). You will be asked to leave your name and address and will be instructed to identify the Announcement number of interest.

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from:

Yolanda I. Gonzalez-Alvarez, Grants Management Specialist, Centers for Disease Control and Prevention (CDC), Procurement and Grants Office, Room 3000, Mailstop E–15, 2520 Brandywine Road, Atlanta, GA 30341–4146, Telephone: (770) 488–2781, E-mail: ybg0@cdc.gov.

For program technical assistance, contact: Leo Weakland, Deputy Coordinator, Global AIDS Activity (GAA), National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Mailstop E–07, Atlanta, GA 30333, Telephone number (404) 639–8016, Email address: lfw0@cdc.gov.


John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 00–16850 Filed 7–3–00; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) Announces the Following Meetings

Name: National HIV Prevention Plan Meetings.

Time and Dates: 9 a.m.–12 p.m. (noon).

Tuesday—July 18, 2000

Hotel Pennsylvania, 401 7th Avenue, New York, NY 10001, Phone: 212–736–5000

Wednesday—July 26, 2000

Crowne Plaza-Houston, 2222 West Loop South, Houston, TX 77027, Phone: 713–961–7272

Thursday—July 27, 2000

Congress Plaza Hotel, 520 South Michigan Avenue, Chicago, IL 60605, Phone: 312–427–3800

Tuesday—August 1, 2000

The Argent Hotel, 50 Third Street, San Francisco, CA 94103, Phone: 415–974–6400

Place: See Above.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

Purpose: To present the current draft of the Centers for Disease Control and Prevention’s National HIV Prevention Strategic Plan and to provide an opportunity for community comment.

Matters To Be Discussed: Agenda items include background and development of the draft National HIV Prevention Strategic Plan; the plan itself; next steps in plan development; and public comments.

Contact Person for More Information:

Lydia Ogden, National Center for HIV, STD, and TB Prevention, Office of Planning and Policy Coordination, 1600 Clifton Road, N.E., M/S E–07, Atlanta, Georgia 30333, telephone 404/639–8031.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.


Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 00–16846 Filed 7–3–00; 8:45 am]
BILLING CODE 4163–18–P